Sarcoma  >>  ID-LV305  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ID-LV305 / Merck (MSD)
Synovate, NCT03520959 / 2018-000824-32: A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Checkmark Started patient enrollment for Phase 3 pivotal trial in synovial sarcoma [SYNOVATE]
Aug 2018 - Aug 2018: Started patient enrollment for Phase 3 pivotal trial in synovial sarcoma [SYNOVATE]
Terminated
3
1
Canada, US
LV305, G305, LV305-matching placebo, G305-matching placebo
Immune Design
Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
11/18
11/18

Download Options